Literature DB >> 15015902

Antipsychotic-induced rabbit syndrome: epidemiology, management and pathophysiology.

Miguel Schwartz1, Shraga Hocherman.   

Abstract

Rabbit syndrome is an antipsychotic-induced rhythmic motion of the mouth/lips, resembling the chewing movements of a rabbit. The movement consists of a vertical-only motion, at about 5Hz, with no involvement of the tongue. Usually, the involuntary movements associated with rabbit syndrome appear after a long period (in most cases months or years) of antipsychotic treatment; however, a few patients with the syndrome have had treatment histories with no antipsychotic involvement. The reported prevalence of rabbit syndrome ranges from 2.3 to 4.4% of patients treated with typical antipsychotics. There have been isolated reports of rabbit syndrome in patients treated with the atypical agents risperidone and clozapine. Patients with rabbit syndrome are most often misdiagnosed as having oral tardive dyskinesia. In such cases the key for correct diagnosis is the involvement of tardive tongue movements, which does not occur in rabbit syndrome. The treatment of rabbit syndrome is empirical, reflecting poor understanding of its neuropathology. The first step is to reduce the amount of antipsychotic treatment as much as possible. However, since, in most cases, full withdrawal of antipsychotic treatment is impossible, the syndrome cannot be completely abolished without additional measures. The next stage of treatment involves specific drugs that aim to control the syndrome. Anticholinergic drugs are the best known treatment. Rabbit syndrome does not respond to treatment with levodopa or dopamine agonists. The most striking aspect of this syndrome is its specificity. Rabbit syndrome affects only the buccal region, and within this area it involves a highly stereotyped involuntary movement. This immediately focuses attention on the basal ganglia, in particular the substantia nigra pars reticulata, which is also implicated in oral dyskinesia. Continuing neurophysiological and pharmacological research of the basal ganglia holds the key to better understanding and treatment of this syndrome in the coming years.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15015902     DOI: 10.2165/00023210-200418040-00002

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  38 in total

1.  Rabbit syndrome treated with olanzapine.

Authors:  R Durst; G Katz; J Zislin; S Raskin; I Kalman
Journal:  Br J Psychiatry       Date:  2000-02       Impact factor: 9.319

2.  The role of nigral and thalamic output pathways in the expression of oral stereotypies induced by amphetamine injections into the striatum.

Authors:  J J Canales; G Gilmour; S D Iversen
Journal:  Brain Res       Date:  2000-02-21       Impact factor: 3.252

3.  Reversal of rabbit syndrome with olanzapine.

Authors:  S S Damodaran; J K Thankamma
Journal:  Aust N Z J Psychiatry       Date:  2000-02       Impact factor: 5.744

Review 4.  Organization of the basal ganglia: the importance of axonal collateralization.

Authors:  A Parent; F Sato; Y Wu; J Gauthier; M Lévesque; M Parent
Journal:  Trends Neurosci       Date:  2000-10       Impact factor: 13.837

Review 5.  Functional significance of the cortico-subthalamo-pallidal 'hyperdirect' pathway.

Authors:  Atsushi Nambu; Hironobu Tokuno; Masahiko Takada
Journal:  Neurosci Res       Date:  2002-06       Impact factor: 3.304

Review 6.  Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions.

Authors:  G Di Chiara; M Morelli; S Consolo
Journal:  Trends Neurosci       Date:  1994-06       Impact factor: 13.837

Review 7.  Parkinson's disease. Second of two parts.

Authors:  A E Lang; A M Lozano
Journal:  N Engl J Med       Date:  1998-10-15       Impact factor: 91.245

8.  Prevalence of the rabbit syndrome.

Authors:  R Yassa; S Lal
Journal:  Am J Psychiatry       Date:  1986-05       Impact factor: 18.112

9.  Temporal and spatial characteristics of tonically active neurons of the primate's striatum.

Authors:  T Aosaki; M Kimura; A M Graybiel
Journal:  J Neurophysiol       Date:  1995-03       Impact factor: 2.714

10.  Rabbit syndrome and tardive dyskinesia: two complications of chronic neuroleptic treatment.

Authors:  M Schwartz; B Weller; M Erdreich; B Sharf
Journal:  J Clin Psychiatry       Date:  1995-05       Impact factor: 4.384

View more
  8 in total

1.  Antipsychotic-Induced Rabbit Syndrome in a Pediatric Patient.

Authors:  James Nataraj; Rekha Jabbal
Journal:  Can J Hosp Pharm       Date:  2015 Nov-Dec

2.  Rabbit syndrome associated with medullary compression by vertebral artery.

Authors:  Hyung-Eun Park; Ji-Eun Lee; Byung-Chul Son; Joong-Seok Kim
Journal:  Neurol Sci       Date:  2016-02-12       Impact factor: 3.307

Review 3.  [Rare tremor syndromes].

Authors:  J S Becktepe; F Goevert; G Deuschl
Journal:  Nervenarzt       Date:  2018-04       Impact factor: 1.214

4.  Lurasidone-Induced Rabbit Syndrome: A Case Report.

Authors:  Jared L Reichenberg; Kathryn K Ridout; Kenneth C Rickler
Journal:  J Clin Psychiatry       Date:  2017-05       Impact factor: 4.384

Review 5.  Cranial movement disorders: clinical features, pathophysiology, differential diagnosis and treatment.

Authors:  Giovanni Fabbrini; Giovanni Defazio; Carlo Colosimo; Philip D Thompson; Alfredo Berardelli
Journal:  Nat Clin Pract Neurol       Date:  2009-02

6.  Clozapine-induced rabbit syndrome: a case report.

Authors:  Cicek Hocaoglu
Journal:  Ment Illn       Date:  2009-10-30

7.  A Report of Rabbit Syndrome Who Benefited from Sigma 1 Agonist Fluvoxamine.

Authors:  Yakup Albayrak; Murat Beyazyüz; Özlem Abbak; Ece Altındağ
Journal:  Clin Psychopharmacol Neurosci       Date:  2019-02-28       Impact factor: 2.582

8.  Neurobiological mechanisms associated with antipsychotic drug-induced dystonia.

Authors:  Anton Jm Loonen; Svetlana A Ivanova
Journal:  J Psychopharmacol       Date:  2020-09-09       Impact factor: 4.153

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.